Bill > SB253

This bill addresses restrictions on drug manufacturers' practices related to the federal 340B Drug Pricing Program, which is a program that allows certain healthcare providers to purchase prescription drugs at discounted prices. Specifically, the bill prohibits drug manufacturers, their agents, affiliates, distributors, or logistics providers from: (1) denying or restricting the acquisition or delivery of 340B covered drugs to authorized locations of 340B covered entities (such as certain hospitals, clinics, and healthcare organizations), unless federal law explicitly prohibits the drug's receipt; and (2) requiring 340B covered entities to submit claims or utilization data as a condition for acquiring or receiving 340B covered drugs, unless such data sharing is mandated by federal law. These actions would be considered a violation of the state's consumer protection act, giving affected entities legal recourse if a drug manufacturer improperly interferes with their ability to participate in the 340B Drug Pricing Program. The bill is set to take effect on January 1, 2026, providing drug manufacturers and healthcare providers time to adjust to the new requirements.

Health and Social Services

https://gc.nh.gov/bill_status/legacy/bs2016/bill_status.aspx?lsr=1102&sy=2025&sortoption=&txtsessionyear=2025&txtbillnumber=SB253